{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:07:18Z","timestamp":1793945238740,"version":"4.8.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Verastem Incorporated"},{"DOI":"10.13039\/501100008902","name":"Puerto Rico Science, Technology & Research Trust","doi-asserted-by":"crossref","award":["PRSTRT2022"],"award-info":[{"award-number":["PRSTRT2022"]}],"id":[{"id":"10.13039\/501100008902","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04870-4","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:02:37Z","timestamp":1772776957000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Window of opportunity study measuring defactinib and avutometinib delivery in glioblastomas"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3269-3994","authenticated-orcid":false,"given":"Miguel Mayol","family":"Del Valle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2764-6211","authenticated-orcid":false,"given":"Emely Morales","family":"Colon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavitha","family":"Kettimuthu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2274-4284","authenticated-orcid":false,"given":"Kristal","family":"Maner-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9968-681X","authenticated-orcid":false,"given":"Jeffrey J.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8053-5619","authenticated-orcid":false,"given":"Lilia Y.","family":"Kucheryavykh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"issue":"6","key":"4870_CR1","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","volume":"26","author":"M Price","year":"2024","unstructured":"Price M, Ballard C, Benedetti J et al (2024) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2017\u20132021. Neuro-oncol 26(6):vi1\u2013vi85. https:\/\/doi.org\/10.1093\/neuonc\/noae145","journal-title":"Neuro-oncol"},{"key":"4870_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, van den Bent MJ, Blumenthal DT et al (2023) Vorasidenib in IDH1- or IDH2-Mutant Low-Grade glioma. N Engl J Med 389:589\u2013601. https:\/\/doi.org\/10.1056\/NEJMoa2304194","journal-title":"N Engl J Med"},{"key":"4870_CR3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. New Engl J Med 360:765\u2013773. https:\/\/doi.org\/10.1056\/NEJMoa0808710","journal-title":"New Engl J Med"},{"key":"4870_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699\u2013708. https:\/\/doi.org\/10.1056\/NEJMoa1308573","journal-title":"N Engl J Med"},{"key":"4870_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus Radiotherapy-Temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709\u2013722. https:\/\/doi.org\/10.1056\/NEJMoa1308345","journal-title":"N Engl J Med"},{"key":"4870_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1200\/JCO.2004.08.110","volume":"22","author":"JN Rich","year":"2004","unstructured":"Rich JN, Reardon DA, Peery T et al (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133\u2013142. https:\/\/doi.org\/10.1200\/JCO.2004.08.110","journal-title":"J Clin Oncol"},{"key":"4870_CR7","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/1535-7163.MCT-11-0048","volume":"10","author":"ME Hegi","year":"2011","unstructured":"Hegi ME, Diserens AC, Bady P et al (2011) Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib\u2013a phase II trial. Mol Cancer Ther 10:1102\u20131112. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0048","journal-title":"Mol Cancer Ther"},{"key":"4870_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/noajnl\/vdac157","volume":"4","author":"V Fougner","year":"2022","unstructured":"Fougner V, Hasslebach B, lassen U et al (2022) Implementing targeted therapies in the treatment of glioblastoma: previous shortcomings, future promises, and a multimodal strategy recommendation. Neuro-oncol Adv 4:1\u201311. https:\/\/doi.org\/10.1093\/noajnl\/vdac157","journal-title":"Neuro-oncol Adv"},{"key":"4870_CR9","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1200\/JCO.2007.11.8554","volume":"25","author":"R Stupp","year":"2007","unstructured":"Stupp R, Hegi ME, Gilbert MR, Chakravarti A (2007) Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25:4127\u20134136. https:\/\/doi.org\/10.1200\/JCO.2007.11.8554","journal-title":"J Clin Oncol"},{"key":"4870_CR10","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1093\/neuonc\/noaa149","volume":"22","author":"MA Vogelbaum: Vogelbaum","year":"2020","unstructured":"Vogelbaum: Vogelbaum MA, Krivosheya D, Borghei-Razavi H et al (2020) Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. Neuro-Oncol 22:1568\u20131579. https:\/\/doi.org\/10.1093\/neuonc\/noaa149","journal-title":"Neuro-Oncol"},{"key":"4870_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/onc.2009.333","volume":"29","author":"JP Robinson","year":"2010","unstructured":"Robinson JP, VanBrocklin MW, Guilbeault AR, Signorelli DL, Brandner S, Holmen SL (2010) Activated BRAF induces gliomas in mice when combined with Ink4a\/Arf loss or Akt activation. Oncogene 29:335\u2013344. https:\/\/doi.org\/10.1038\/onc.2009.333","journal-title":"Oncogene"},{"issue":"24","key":"4870_CR12","doi-asserted-by":"publisher","first-page":"6160","DOI":"10.3390\/cancers13246160","volume":"13","author":"RE Nu\u00f1ez","year":"2021","unstructured":"Nu\u00f1ez RE, Del Valle MM, Ortiz K, Almodovar L, Kucheryavykh L (2021) Microglial cytokines induce invasiveness and proliferation of human glioblastoma through Pyk2 and FAK activation. Cancers (Basel) 13(24):6160. https:\/\/doi.org\/10.3390\/cancers13246160","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4870_CR13","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1186\/s12885-021-08733-4","volume":"21","author":"Y Makino","year":"2021","unstructured":"Makino Y, Arakawa Y, Yoshioka E, Shofuda T, Minamiguchi S, Kawauchi T et al (2021) Infrequent RAS mutation is not associated with specific histological phenotype in gliomas. BMC Cancer 21(1):1025. https:\/\/doi.org\/10.1186\/s12885-021-08733-4","journal-title":"BMC Cancer"},{"key":"4870_CR14","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/neuonc\/noab247","volume":"24","author":"LJ Andrews","year":"2022","unstructured":"Andrews LJ, Thornton ZA, Saincher SS, Yao IY, Dawson S, McGuinness LA et al (2022) Prevalence of BRAFV600 in glioma and use of BRAF inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review. Neuro Oncol 24:528\u2013540. https:\/\/doi.org\/10.1093\/neuonc\/noab247","journal-title":"Neuro Oncol"},{"issue":"5","key":"4870_CR15","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1593\/neo.08206","volume":"10","author":"Y Lyustikman","year":"2008","unstructured":"Lyustikman Y, Momota H, Pao W, Holland E (2008) Constitutive activation of Raf-1 induces glioma formation in mice. Neoplasia 10(5):501\u2013510. https:\/\/doi.org\/10.1593\/neo.08206","journal-title":"Neoplasia"},{"key":"4870_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RG Verhaak","year":"2010","unstructured":"Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98\u2013110. https:\/\/doi.org\/10.1016\/j.ccr.2009.12.020","journal-title":"Cancer Cell"},{"issue":"6","key":"4870_CR17","doi-asserted-by":"publisher","first-page":"e9856","DOI":"10.15252\/emmm.201809856","volume":"11","author":"S Xiaojing Wang","year":"2019","unstructured":"Xiaojing Wang S, Min H, Liu N, Wu X, Liu T, Wang W, Li Y, Shen H, Wang Z, Qian H, Xu C, Zhao Y, Chen (2019) Nf1 loss promotes Kras-driven lung adenocarcinoma and results in Psat1-mediated glutamate dependence. EMBO Mol Med 11(6):e9856. https:\/\/doi.org\/10.15252\/emmm.201809856","journal-title":"EMBO Mol Med"},{"issue":"1","key":"4870_CR18","doi-asserted-by":"publisher","first-page":"vdad132","DOI":"10.1093\/noajnl\/vdad132","volume":"5","author":"S de Khan","year":"2023","unstructured":"Khan S, Martinez-Ledesma E, Dong J, Mahalingam R, Park SY, Piao Y, Koul D, Balasubramaniyan V, de Groot JF, Yung WKA (2023) Neuronal differentiation drives the antitumor activity of mitogen-activated protein kinase kinase (MEK) inhibition in glioblastoma. Neurooncol Adv 5(1):vdad132. https:\/\/doi.org\/10.1093\/noajnl\/vdad132","journal-title":"Neurooncol Adv"},{"issue":"11","key":"4870_CR19","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1093\/neuonc\/nox044","volume":"19","author":"RS Van McNeill","year":"2017","unstructured":"McNeill RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DM, Bash RE, Angus SP, Herring LE, Simon JM, Skinner KR, Limas JC, Chen X, Schmid RS, Siegel MB, Van Swearingen AED, Hadler MJ, Sulman EP, Sarkaria JN, Anders CK, Graves LM, Berens ME, Johnson GL, Miller CR (2017) Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. Neuro Oncol 19(11):1469\u20131480. https:\/\/doi.org\/10.1093\/neuonc\/nox044","journal-title":"Neuro Oncol"},{"issue":"7","key":"4870_CR20","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1091\/mbc.e10-08-0725","volume":"22","author":"TB Deramaudt","year":"2011","unstructured":"Deramaudt TB, Dujardin D, Hamadi A, Noulet F, Kolli K, De Mey J et al (2011) FAK phosphorylation at Tyr-925 regulates cross-talk between focal adhesion turnover and cell protrusion. Mol Biol Cell Apr 22(7):964\u2013975","journal-title":"Mol Biol Cell Apr"},{"issue":"5","key":"4870_CR21","first-page":"323","volume":"1","author":"CA Lipinski","year":"2003","unstructured":"Lipinski CA, Tran NL, Bay C, Kloss J, McDonough WS, Beaudry C, Berens ME, Loftus JC (2003) Differential role of proline-rich tyrosine kinase 2 and focal adhesion kinase in determining glioblastoma migration and proliferation. Mol Cancer Res Mar 1(5):323\u2013332 PMID: 12651906","journal-title":"Mol Cancer Res Mar"},{"issue":"6","key":"4870_CR22","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1158\/1535-7163.MCT-08-1055","volume":"8","author":"JC Loftus","year":"2009","unstructured":"Loftus JC, Yang Z, Tran NL, Kloss J, Viso C, Berens ME, Lipinski CA (2009) The Pyk2 FERM domain as a target to inhibit glioma migration. Mol Cancer Ther Jun 8(6):1505\u20131514. https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-1055Epub 2009 Jun 9. PMID: 19509258; PMCID: PMC3180876","journal-title":"Mol Cancer Ther Jun"},{"issue":"5","key":"4870_CR23","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1593\/neo.04712","volume":"7","author":"CA Lipinski","year":"2005","unstructured":"Lipinski CA, Tran NL, Menashi E, Rohl C, Kloss J, Bay RC, Berens ME, Loftus JC (2005) The tyrosine kinase pyk2 promotes migration and invasion of glioma cells. Neoplasia May 7(5):435\u2013445. https:\/\/doi.org\/10.1593\/neo.04712PMID: 15967096; PMCID: PMC1501165","journal-title":"Neoplasia May"},{"key":"4870_CR24","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1038\/sj.onc.1207541","volume":"23","author":"TP Hecker","year":"2004","unstructured":"Hecker TP, Ding Q, Rege TA, Hanks SK, Gladson CL (2004) Overexpression of FAK promotes Ras activity through the formation of a FAK\/p120RasGAP complex in malignant Astrocytoma cells. Oncogene 23:3962\u20133971","journal-title":"Oncogene"},{"issue":"6","key":"4870_CR25","doi-asserted-by":"publisher","first-page":"e0131059","DOI":"10.1371\/journal.pone.0131059","volume":"10","author":"K Rol\u00f3n-Reyes","year":"2015","unstructured":"Rol\u00f3n-Reyes K, Kucheryavykh YV, Cubano LA, Inyushin M, Skatchkov SN, Misty J, Eaton MJ et al (2015) Microglia Activate Migration of Glioma Cells through a Pyk2 Intracellular Pathway. PLoS One 10(6):e0131059 https:\/\/doi.org\/10.1371\/journal.pone.0131059","journal-title":"PLoS One"},{"issue":"3","key":"4870_CR26","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s11060-023-04260-3","volume":"161","author":"J Ortiz\u2013Rivera","year":"2023","unstructured":"Ortiz\u2013Rivera J, Nu\u00f1ez R, Kucheryavykh Y, Kucheryavykh L (2023) The PYK2 inhibitor PF\u2013562271 enhances the effect of Temozolomide on tumor growth in a C57Bl\/6\u2013Gl261 mouse glioma model. J Neurooncol Feb 161(3):593\u2013604. https:\/\/doi.org\/10.1007\/s11060-023-04260-3","journal-title":"J Neurooncol Feb"},{"key":"4870_CR27","doi-asserted-by":"publisher","first-page":"13467","DOI":"10.3390\/ijms241713467","volume":"24","author":"J Ortiz Rivera","year":"2023","unstructured":"Ortiz Rivera J, Velez Crespo G, Inyushin M et al (2023) Pyk2\/FAK signaling is upregulated in recurrent glioblastoma tumors in a C57BL\/6\/GL261 glioma implantation model. Int J Mol Sci 24:13467. https:\/\/doi.org\/10.3390\/ijms241713467","journal-title":"Int J Mol Sci"},{"key":"4870_CR28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ygyno.2024.01.028","volume":"183","author":"B McNamara","year":"2024","unstructured":"McNamara B, Demirkiran C, Hartwich TMP et al (2024) Preclinical efficacy of RAF\/MEK clamp Avutometinib in combination with FAK Inhibition in low grade serous ovarian cancer. Gynecol Oncol 183:133\u2013140. https:\/\/doi.org\/10.1016\/j.ygyno.2024.01.028","journal-title":"Gynecol Oncol"},{"key":"4870_CR29","doi-asserted-by":"publisher","unstructured":"Banerjee S, Krebs MG, Greystoke A Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial. Nat Med 31: 3074\u20133080 (2025)., Jackson GA, Adamson DC et al (2025) (2025) Similarities in Mechanisms of Ovarian Cancer Metastasis and Brain Glioblastoma Multiforme Invasion Suggest Common Therapeutic Targets. Cells 14:171 https:\/\/doi.org\/10.3390\/cells14030171","DOI":"10.3390\/cells14030171"},{"key":"4870_CR30","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1200\/JCO.2006.06.2323","volume":"24","author":"TF Cloughesy","year":"2006","unstructured":"Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, Yung WK, Aldape K, Wright J, Lamborn KR, Prados MD (2006) Phase II trial of Tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American brain tumor consortium study. J Clin Oncol 24:3651\u20133656. https:\/\/doi.org\/10.1200\/JCO.2006.06.2323","journal-title":"J Clin Oncol"},{"issue":"2","key":"4870_CR31","doi-asserted-by":"publisher","first-page":"112868","DOI":"10.1016\/j.yexcr.2021.112868","volume":"408","author":"J Liu","year":"2021","unstructured":"Liu J, Xue L, Xu X, Luo J, Zhang S (2021) FAK-targeting PROTAC demonstrates enhanced antitumor activity against KRAS mutant non-small cell lung cancer. Exp Cell Res 408(2):112868. https:\/\/doi.org\/10.1016\/j.yexcr.2021.112868","journal-title":"Exp Cell Res"},{"issue":"4","key":"4870_CR32","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.ccell.2015.03.008","volume":"13","author":"E Hirata","year":"2015","unstructured":"Hirata E, Girotti MR, Viros A, Hooper S, Spencer-Dene B, Matsuda M, Larkin J, Marais R, Sahai E (2015) Intravital imaging reveals how BRAF Inhibition generates drug-tolerant microenvironments with high integrin beta1\/FAK signaling. Cancer Cell 13(4):574\u2013588. https:\/\/doi.org\/10.1016\/j.ccell.2015.03.008","journal-title":"Cancer Cell"},{"issue":"Supplement 5","key":"4870_CR33","doi-asserted-by":"publisher","first-page":"S728","DOI":"10.1016\/j.annonc.2021.08.1168","volume":"32","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, Grochet R, Shinde R et al (2021) Phase I study of the combination of the dual RAF\/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: results of efficacy in low grade serous ovarian cancer. Ann Oncol 32(Supplement 5):S728 Meeting Abstract","journal-title":"Ann Oncol"},{"key":"4870_CR34","doi-asserted-by":"publisher","first-page":"1724278","DOI":"10.3389\/fonc","volume":"15","author":"A Sagerer","year":"2025","unstructured":"Sagerer A, Ey\u00fcpoglu IY, Juratli TA, Cordes N (2025) Context-specific targeting of focal adhesion kinase in brain tumors: lessons from glioblastoma and neurofibromatosis type 2-mutant meningioma. Front Oncol 15:1724278. https:\/\/doi.org\/10.3389\/fonc","journal-title":"Front Oncol"},{"issue":"5","key":"4870_CR35","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3390\/pharmaceutics17050549","volume":"17","author":"M Furqan","year":"2025","unstructured":"Furqan M, Elliott RJR, Nagle PWK, Dawson JC, Masalmeh R, Garcia VA, Munro AF, Drake C, Morrison GM, Pollard SM, Ebner D, Brunton VG, Frame MC, Carragher NO (2025) Drug Combinations Targeting FAK and MEK Overcomes Tumor Heterogeneity in Glioblastoma. Pharmaceutics 17(5):549. https:\/\/doi.org\/10.3390\/pharmaceutics17050549","journal-title":"Pharmaceutics"},{"key":"4870_CR36","doi-asserted-by":"publisher","unstructured":"Price M, Ballard C, Benedetti J, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS, Ostrom QT (2024) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017\u20132021, Neuro-Oncol, 26, Supplement 6, Pages vi1\u2013vi85. https:\/\/doi.org\/10.1093\/neuonc\/noae145","DOI":"10.1093\/neuonc\/noae145"},{"issue":"1","key":"4870_CR37","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-025-02267-0","volume":"24","author":"A Pouyan","year":"2025","unstructured":"Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A, Hashemi M (2025) Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. Mol Cancer 24(1):58. https:\/\/doi.org\/10.1186\/s12943-025-02267-0","journal-title":"Mol Cancer"},{"issue":"1","key":"4870_CR38","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s11033-024-09996-3","volume":"51","author":"S Hasan","year":"2024","unstructured":"Hasan S, Mahmud Z, Hossain M, Islam S (2024) Harnessing the role of aberrant cell signaling pathways in glioblastoma multiforme: a prospect towards the targeted therapy. Mol Biol Rep 51(1):1069. https:\/\/doi.org\/10.1007\/s11033-024-09996-3","journal-title":"Mol Biol Rep"},{"key":"4870_CR39","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.21873\/anticanres.17295","volume":"44","author":"SL Zeller","year":"2024","unstructured":"Zeller SL, Spirollari E, Chandy AM, Hanft SJ, Gandhi CD, Jhanwar-Uniyal M (2024) Understanding the genomic landscape of glioblastoma: opportunities for targeted therapies. Anticancer Res 44:4677\u20134690. https:\/\/doi.org\/10.21873\/anticanres.17295","journal-title":"Anticancer Res"},{"issue":"1","key":"4870_CR40","doi-asserted-by":"publisher","first-page":"189059","DOI":"10.1016\/j.bbcan.2023.189059","volume":"1879","author":"V Pasupuleti","year":"2024","unstructured":"Pasupuleti V, Vora L, Prasad R, Nandakumar DN, Khatri DK (2024) Glioblastoma preclinical models: strengths and weaknesses. Biochim Biophys Acta Rev Cancer Jan 1879(1):189059. https:\/\/doi.org\/10.1016\/j.bbcan.2023.189059","journal-title":"Biochim Biophys Acta Rev Cancer Jan"},{"key":"4870_CR41","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/S1470-2045(20)30464-2","volume":"21","author":"C Guo","year":"2020","unstructured":"Guo C, Ch\u00e9nard-Poirier M, Roda D, de Miguel M, Harris SJ, Candilejo IM, Sriskandarajah P, Xu W, Scaranti M, Constantinidou A, King J, Parmar M, Turner AJ, Carreira S, Riisnaes R, Finneran F, Hall E, Ishikawa Y, Nakai K, Tunariu N, Basu B, Kaiser M, Lopez JS, Minchom A, de Bono JS, Banerji U (2020) Intermittent schedules of the oral RAF\u2013MEK inhibitor CH5126766\/VS-6766 in patients with RAS\/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Lancet Oncol 21:1478\u20131488. https:\/\/doi.org\/10.1016\/S1470-2045(20)30464-2","journal-title":"Lancet Oncol"},{"key":"4870_CR42","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s10637-015-0282-y","volume":"33","author":"SF Jones","year":"2015","unstructured":"Jones SF, Siu LL, Bendell JC, Cleary JM, Razak ARA, Infante JR, Pandya SS, Bedard PL, Pierce KJ, Houk B, Roberts WG, Shreeve SM, Shapiro GI (2015) A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs 33:1100\u20131107. https:\/\/doi.org\/10.1007\/s10637-015-0282-y","journal-title":"Invest New Drugs"},{"key":"4870_CR43","doi-asserted-by":"publisher","first-page":"7120","DOI":"10.3390\/jcm12227120","volume":"12","author":"V Bourdin","year":"2023","unstructured":"Bourdin V, Bigot W, Vanjak A, Burlacu R, Lopes A, Champion K, Depond A, Amador-Borrero B, Sene D, Comarmond C et al (2023) Drug\u2013Drug interactions involving dexamethasone in clinical practice: myth or reality? J Clin Med 12:7120. https:\/\/doi.org\/10.3390\/jcm12227120","journal-title":"J Clin Med"},{"issue":"12","key":"4870_CR44","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/neuonc\/noy078","volume":"20","author":"NF Brown","year":"2018","unstructured":"Brown NF, Williams M, Arkenau HT, Fleming RA, Tolson J, Yan L, Zhang J, Singh R, Auger KR, Lenox L, Cox D, Lewis Y, Plisson C, Searle G, Saleem A, Blagden S, Mulholland P (2018) A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11 C]GSK2256098. Neuro Oncol 20(12):1634\u20131642. https:\/\/doi.org\/10.1093\/neuonc\/noy078","journal-title":"Neuro Oncol"},{"issue":"8","key":"4870_CR45","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1124\/dmd.114.058339","volume":"42","author":"S Vaidhyanathan","year":"2014","unstructured":"Vaidhyanathan S, Mittapalli RK, Sarkaria JN, Elmquist WF (2014) Factors influencing the CNS distribution of a novel MEK-1\/2 inhibitor: implications for combination therapy for melanoma brain metastases. Drug Metab Dispos Aug 42(8):1292\u20131300. https:\/\/doi.org\/10.1124\/dmd.114.058339","journal-title":"Drug Metab Dispos Aug"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04870-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04870-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04870-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:02:40Z","timestamp":1772776960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04870-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4870"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04870-4","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lilia Kucheryavykh has received research support from Puerto Rico Science, Technology & Research Trust grant number PRSTRT2022. Jeffrey Olson has received funding for the conduct of this study from Verastem, Inc. Miguel Mayol del Valle has received salary support and training from Winn Diversity Career Development Award; Hispanic Center of Excellence, travel support from Hispanic Center of Excellence Research Fellowship Program, and speaker compensation from AHOMPR 2024 Annual Meeting.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}